GORE® SYNECOR Biomaterial is not authorized for use in Canada.

contract-relationship-red

Data Summary

Long-term follow up:

  • 30 days to 2.1 years
  • Patients: 298
  • Robotic, laparoscopic and open approach
  • Retromuscular repairs including totally extraperitoneal (TEP) and transversus abdominis muscle release (TAR) including bridging
  • Preperitoneal placement 
economic-value-2-red

Quality outcomes

  • Hernia recurrence: 0–4.5%
  • Seroma: 4.5–15%
  • Surgical site infection (SSI): 0–10%
  • Surgical site occurrence requiring procedural intervention (SSOPI): 0–10%
  • Complete mesh removals: ZERO 
surgery-red

Patient characteristics

  • Mean body mass index (BMI): > 30 kg/m1
  • Diabetes mellitus
  • Tobacco users
  • Immunosuppressed
  • History of wound infections
  • Recurrent hernias 

1. Lighter M, Roberts J. The role of biosynthetic mesh in abdominal wall hernia repair in the setting of obesity, recurrence and high risk patients. Presented at the 2019 AHS Annual Meeting; March 11-14, 2019; Las Vegas, NV. Hernia 2019;23(Supplement 1):S96-S97. P-1256.

2. Landry M, Grimesly L, Gorman B, et al. Clinical Quality Improvement (CQI): evaluating the real work use of a new hybrid hernia mesh. Presented at the 2018 International Hernia Congress Program; March 12, 2018; Miami Beach, FL.

3. Rios-Diaz A, Hitchner M, Christopher AN, Broach R, Cunning JR, Fischer JP. Early clinical and patient-reported outcomes of a new hybrid mesh for incisional hernia repair. Journal of Surgical Research 2021;265:49-59.

4. Kudsi OY, Gokcal F. Lateral approach totally extraperitoneal (TEP) robotic retromuscular ventral hernia repair. Hernia 2021;25(1):211-222.

5. Kudsi OY, Chang K, Bou-Ayash N, Gokcal F. Hybrid robotic hernia repair for incisional hernias: perioperative and patient-reported outcomes. Journal of Laparoendoscopic & Advanced Surgical Techniques. Part A. 2021;31(5):570-578.

IFU Consult instructions

Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. RXOnly

INDICATIONS FOR USE: The GORE® SYNECOR Intraperitoneal Biomaterial device is intended for use in the repair of hernias and abdominal wall or thoracic wall soft tissue deficiencies that may require the addition of a nonabsorbable reinforcing or bridging material.

CONTRAINDICATIONS: The GORE® SYNECOR Intraperitoneal Biomaterial is contraindicated for use in reconstruction of cardiovascular defects.

INDICATIONS FOR USE: The GORE® SYNECOR Preperitoneal Biomaterial device is intended for use in the repair of hernias and abdominal wall soft tissue deficiencies that may require the addition of a non-absorbable reinforcing or bridging material.  

CONTRAINDICATIONS: The GORE® SYNECOR Preperitoneal Biomaterial is contraindicated for use in reconstruction of cardiovascular defects.

24GP1096-EN01